Physician profile
Brian C Sninsky
NPI 1336568807
$10,822.33
in general payments reported to CMS, 2019-2025
27 companies · $197 in 2025
The $197 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $404 · 2020: $458 · 2021: $591 · 2022: $330 · 2023: $7,132 · 2024: $1,710 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,541 · Food and Beverage: $498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,541.00 |
| Food and Beverage | $497.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verathon INC. | $8,541.00 | 2023-2024 | Npd Clinical Study & Bladder Scanner, Npd Clinical Study |
| Boston Scientific Corporation | $286.25 | 2020-2025 | Ams 700 |
| Astellas Pharma US INC | $212.27 | 2019-2025 | Xtandi |
| Pfizer INC. | $202.29 | 2019-2025 | |
| Teleflex LLC | $168.13 | 2021-2024 | Urolift |
| Myovant Sciences INC. | $156.61 | 2021-2022 | |
| Neotract INC. | $149.63 | 2020 | |
| Endo Pharmaceuticals INC. | $143.96 | 2019-2023 | Aveed, Xiaflex |
| Janssen Biotech, INC. | $137.30 | 2019-2022 | |
| Coloplast Corp | $115.83 | 2021-2024 | Isiris Astent Removal Device |
| Abbvie INC. | $85.20 | 2019-2025 | |
| Urovant Sciences INC | $71.15 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $68.37 | 2019-2024 | |
| Endo USA, INC. | $63.66 | 2024-2025 | Aveed, Xiaflex |
| Antares Pharma, INC. | $56.33 | 2020-2024 | Xyosted |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $55.40 | 2024-2025 | Gemtesa, Orgovyx |
| Merck Sharp & Dohme LLC | $55.00 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Allergan, INC. | $40.81 | 2019-2022 | |
| Photocure INC | $34.14 | 2024-2025 | Cysview |
| Tolmar Pharmaceuticals, INC. | $34.02 | 2020-2021 | |
| Angiodynamics, INC. | $33.33 | 2022 | |
| Calyxo, INC. | $30.39 | 2024 | Cvac Aspiration System |
| Aytu Biopharma, INC. | $20.60 | 2019 | |
| 180 Medical, INC. | $17.77 | 2020 | |
| Dornier Medtech America, INC | $17.68 | 2019 | |
| Clarus Therapeutics INC. | $13.78 | 2021 | |
| Zyla Life Sciences, INC. | $11.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Sninsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.